TY - JOUR
T1 - Improving graft survival for patients undergoing liver transplantation
AU - Dickson, Rolland C.
AU - Pungpapong, Surakit
AU - Keaveny, Andrew P.
AU - Taner, C. Burcin
AU - Ghabril, Marwan
AU - Aranda-Michel, Jaime
AU - Satyanarayana, Raj
AU - Bonatti, Hugo
AU - Kramer, David J.
AU - Nguyen, Justin H.
PY - 2011/5/1
Y1 - 2011/5/1
N2 - Liver transplant (LT) outcomes are reported to be improving in non-HCV recipients but not for those infected with HCV. Our aim was to evaluate graft survival and predictors of outcome in HCV and non-HCV patients before and after 2003. Patients with primary LT between February 1, 1998, and December 31, 2005, were included. Patients were divided into Era 1 (1998-2002) and Era 2 (2003-2005) with follow-up through May 31, 2009. Graft survival was compared for HCV, non-HCV, and all patients. There was significant improvement in graft survival in Era 2 for HCV patients. Graft survival in Era 2 of HCV patients was equivalent to non-HCV patients. The most significant improvement between eras was in outcomes of grafts from donors ≥60yr with three-yr graft survival 58.6 (51.3-65.9) vs. 75.4 (68.9-81.9), p=0.002. The use of donors ≥60 did not change between eras: 31% vs. 34%; however, utilization in HCV recipients decreased from 36% to 3% (p<0.001). In conclusion, graft survival of HCV patients has improved significantly since 2003 and was comparable to non-HCV patients up to threeyr. The change in management of donor organs into HCV and non-HCV patients likely contributed to this outcome.
AB - Liver transplant (LT) outcomes are reported to be improving in non-HCV recipients but not for those infected with HCV. Our aim was to evaluate graft survival and predictors of outcome in HCV and non-HCV patients before and after 2003. Patients with primary LT between February 1, 1998, and December 31, 2005, were included. Patients were divided into Era 1 (1998-2002) and Era 2 (2003-2005) with follow-up through May 31, 2009. Graft survival was compared for HCV, non-HCV, and all patients. There was significant improvement in graft survival in Era 2 for HCV patients. Graft survival in Era 2 of HCV patients was equivalent to non-HCV patients. The most significant improvement between eras was in outcomes of grafts from donors ≥60yr with three-yr graft survival 58.6 (51.3-65.9) vs. 75.4 (68.9-81.9), p=0.002. The use of donors ≥60 did not change between eras: 31% vs. 34%; however, utilization in HCV recipients decreased from 36% to 3% (p<0.001). In conclusion, graft survival of HCV patients has improved significantly since 2003 and was comparable to non-HCV patients up to threeyr. The change in management of donor organs into HCV and non-HCV patients likely contributed to this outcome.
KW - Hepatitis C
KW - Liver transplantation
UR - http://www.scopus.com/inward/record.url?scp=79958712591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79958712591&partnerID=8YFLogxK
U2 - 10.1111/j.1399-0012.2011.01428.x
DO - 10.1111/j.1399-0012.2011.01428.x
M3 - Article
C2 - 21429010
AN - SCOPUS:79958712591
SN - 0902-0063
VL - 25
SP - E345-E355
JO - Clinical Transplantation
JF - Clinical Transplantation
IS - 3
ER -